MyoPax: We repair muscle – the human muscle stem cell


PRINCIPAL INVESTIGATORS:
Prof. Dr. Simone Spuler,
Dr. Verena Schöwel
MDC & Charité

ATMP

Stem cells

2018

Track 2

SUMMARY

Muscle wasting and weakness are leading symptoms of a wide variety of diseases. The entire muscle can be affected or only single muscles do not function, yet with dramatic impairment of life quality and life-threatening consequences. Muscle diseases are currently untreatable. In Europe alone, over 6 million citizens are affected. The team MyoPax develops an innovative autologous muscle stem cell therapy to treat muscle wasting. The team's technological innovation enables highly standardized manufacturing of pure, native and highly regenerative muscle stem cells from small human muscle tissue specimens to treat acquired and inherited muscle diseases. The team has acquired follow-up funding and prepares to set up a startup company to clinically pursue the development of their approach to fight muscle diseases.

PROJECT ACHIEVEMENTS DURING SPARK

- Preclinical proof-of-concept, preclinical safety, PEI scientific advice meetings
- Planning of phase I/IIa clinical trial
- Follow-on funding acquired: BMBF 2020 for clinical trial, Helmholtz Enterprise 2018-2019, IBB Coaching Bonus 2019, Translatorik program of the Else Kröner-Fresenius Foundation 2019-2020, Helmholtz Validation Fund 2020-2022, SPOT MDC Spin-Off Support 2020-21
- Science4Life award 2019 for "MyoPax" business concept, Charité Entrepreneur-ship summit award winner 2019
- Pitch contribution at Bio-Europe 2017, World Health Summit 2019, 9th BioM BioAngels Event 2020
- BMBF Funding for clinical study in 2021

LONG-TERM GOALS

- Founding of a startup company in 2022
- Running the first in human clinical study in 2021

PREVIOUS SPARK FUNDING

- Track 1 2016